palivizumab biosimilar / iBio - LARVOL DELTA

Palivizumab for Severe Respiratory Syncytial Virus Infection in Immunocompetent Adults: A Case Series. (PubMed, Infect Drug Resist) - "These cases suggest that Palivizumab may be a potential therapeutic option for severe RSV infection in immunocompetent adults. Further research, including randomized controlled trials, is needed to confirm these preliminary findings and establish optimal dosing and treatment protocols."

Journal • Brain Cancer • Cardiovascular • Hypertension • Infectious Disease • Meningioma • Oncology • Respiratory Diseases • Respiratory Syncytial Virus Infections • Solid Tumor

Nationwide Epidemiology and Outpatient Healthcare Resource Use of Children with Respiratory Syncytial Virus from 2005 to 2021. (PubMed, J Pediatric Infect Dis Soc) - "Our study highlights the changes in epidemiology and outpatient health resource utilization for children with RSV infections. These findings are valuable for policymakers and clinicians aiming to develop strategies, including newly developed maternal vaccines and single-dose long-acting monoclonal antibodies."

Journal • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

RSV-Passive Immunization Reduces Antimicrobial Consumption During RSV Infection in Infants and Young Children -5 Years in Japan (ISPOR-EU 2024) - "Study findings are important in supporting medical decision-making regarding the selection of antiviral treatments, restriction of antibiotic therapy, and infection control strategies for RSV."

Clinical • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Randomized, prospective, single-center, open study on preventing RSV-mediated respiratory sequelae in preterm newborns (ERS 2024) - "Palivizumab (PVZ) is recommended for high-risk infants during bronchiolitis seasons to prevent severe infections. Patients in group B with a birth weight < 2170 g had a higher risk of RSV-related hospitalizations, co-infections, and need for antibiotics and corticosteroids (p .036, .040, .036 and .036, respectively). PVZ resulted effective in preventing short- and long-term respiratory morbidity."

Clinical • Prematurity • Asthma • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Management and outcomes of bronchiolitis in Italy and Latin America: a multi-center, prospective, observational study. (PubMed, Eur J Pediatr) - "We found significant differences in the care for children with bronchiolitis in Italy and LA. Reasons behind such differences are unclear and would require further investigations to optimize and homogenize practice all over the world."

Journal • Observational data • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Respiratory Syncytial Virus Bronchiolitis: Rapid Evidence Review. (PubMed, Am Fam Physician) - "However, prophylaxis with palivizumab may be considered for infants at high risk. Therapies such as bronchodilators, epinephrine, nebulized hypertonic saline, corticosteroids, antibiotics, and chest physiotherapy are not recommended. Although most episodes of RSV bronchiolitis are self-limited, some children have an increased risk of asthma later in life."

Journal • Review • Asthma • Cough • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

RESPIRATORY SYNCYTIAL VIRUS (RSV)- ASSOCIATED HOSPITALIZATIONS IN A TERTIARY PEDIATRIC DEPARTMENT: A 5-YEAR REVIEW (ESPID 2023) - "Two patients had received at least one dose of Palivizumab. Sixty-five(65) children were included, 33(50.7%) males, with mean age 8.23mo (IQR 6, 70% <6 months of age). In 2018-2020, seasonal peaks were observed Jan-March, while in 2021-2022 peaks were observed Oct-Dec, indicating an earlier season onset. In early December 2022, there was a cluster of RSV cases within 15 days, in children that were hospitalized for other reasons."

Clinical • Review • Cough • Infectious Disease • Inflammation • Novel Coronavirus Disease • Pediatrics • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

STOP RSV: SURVEILLANCE TOWARDS PREVENTING PAEDIATRIC INCIDENCE OF RESPIRATORY SYNCYTIAL VIRUS (RSV) ATTRIBUTABLE RESPIRATORY TRACT INFECTION – PREMATURITY, CO-MORBIDITIES, HEALTHCARE UTILIZATION AND MEDICATION PRESCRIPTION (ESPID 2023) - "Recruits: n=723 of which 18% were born premature <37 weeks (7% <35 weeks) Proportion Underlying Co-morbidity: 22% (78% no underlying co-morbidity noted) Health Care Utilization: 92% of hospital attendances had a previous Primary Care Consultation. Medication: (at time of symptoms): 25% antibiotics, 29% inhalers and 14% corticosteroids. 3% previously administered Palivizumab."

HEOR • Prematurity • Infectious Disease • Pediatrics • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023) (PubMed, Zhonghua Jie He He Hu Xi Za Zhi) - "And the goal of nutritional assessment is to evaluate and monitor whether pediatric patients are achieving normal standards of growth and development or whether adult patients are maintaining adequate nutritional status(1C).Question 12: Does CF require pathological examination as a diagnostic basis?Pathohistological biopsy is not recommended as a first-line diagnostic method in patients with a suspected diagnosis of CF(1D).Question 13: Do CF patients need long-term macrolides?At least 6 months of azithromycin treatment is recommended for CF patients with chronic PA infection(2A).Question 14: Do CF patients need long-term inhalation of hypertonic saline?Long term treatment with hypertonic saline is recommended for patients with CF(1A).Question 15: Do CF patients need long-term inhalation of Dornase alfa(DNase)?Long term use of DNase is recommended in patients with CF aged 6 years and older(1A).Question 16: Do CF patients need inhalation of mannitol?Inhaled mannitol..."

Journal • Allergic Bronchopulmonary Aspergillosis • Anorexia • Asthma • Bronchiectasis • Cardiovascular • Cough • Cystic Fibrosis • Diabetes • Fatigue • Fibrosis • Gastrointestinal Disorder • Genetic Disorders • Hepatology • Hypertension • Immunology • Infectious Disease • Influenza • Metabolic Disorders • Nasal Polyps • Nephrology • Otorhinolaryngology • Pain • Pancreatitis • Pediatrics • Portal Hypertension • Primary Biliary Cholangitis • Pulmonary Disease • Pulmonary Embolism • Rare Diseases • Respiratory Diseases • Respiratory Syncytial Virus Infections • Sinusitis • Transplantation • CFTR

Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. (PubMed, Lancet Child Adolesc Health) - "A single dose of nirsevimab protected healthy infants born at term or preterm from medically attended RSV LRTI, associated hospital admission, and severe RSV. Pharmacokinetic data support efficacy extrapolation to infants with chronic lung disease, congenital heart disease, or extreme prematurity. Together, these data suggest that nirsevimab has the potential to change the landscape of infant RSV disease by reducing a major cause of infant morbidity and the consequent burden on caregivers, clinicians, and health-care providers."

Journal • PK/PD data • Retrospective data • Cardiovascular • Heart Failure • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Current methods of preventing infectious disease and managing febrile neutropenia in childhood cancer patients: a nationwide survey in Japan. (PubMed, Int J Clin Oncol) - "As a whole, intensive care for infectious prophylaxis or FN is applied in Japan; however, the methods vary among centers, and some are excessive or inadequate. Therefore, it is desirable to conduct clinical trials and establish adequate care protocols for infection in children with cancer in Japan."

Journal • Critical care • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • Oncology • Pediatrics • Respiratory Diseases • Respiratory Syncytial Virus Infections

Passive Immunoprophylaxis against Respiratory Syncytial Virus in Children: Where Are We Now? (PubMed, Int J Mol Sci) - "There are a growing number of RSV passive immunization candidates under development intended for RSV prevention in all infants. In this review, we describe the state-of-the-art of palivizumab's usage and summarize the clinical and preclinical trials regarding the development of mAbs with a better cost-effectiveness ratio."

Clinical • Journal • Review • Cardiovascular • CNS Disorders • Heart Failure • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

[VIRTUAL] LEVOFLOXACIN PROPHYLAXIS FOR A PATIENT WITH INFANT ACUTE LYMPHOBLASTIC LEUKEMIA (ASPHO 2021) - "She started induction therapy per AALL15P1, without azacitidine, and the rest of her therapy was based on the Interfant-06 protocol...She also received prophylaxis against invasive candidiasis (micafungin during induction, transitioned to fluconazole), Pneumocystis jiroveci pneumonia (sulfamethoxazole-trimethoprim) and respiratory syncytial virus (palivizumab)...Throughout treatment, she had 2 episodes of febrile neutropenia requiring escalation from levofloxacin prophylaxis, resulting in 14 total days of therapy with cefepime and 1 day of vancomycin... Levofloxacin prophylaxis is recommended in supportive care guidelines for pediatric patients with cancer, primarily for patients with AML or relapsed ALL. Patients with infant ALL are also high risk of infection throughout therapy requiring aggressive supportive care. Levofloxacin prophylaxis could be a potential addition to the supportive care armamentarium for these patients in an attempt to reduce bacteremia and..."

Clinical • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Candidiasis • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • Oncology • Pediatrics • Pneumonia • Respiratory Diseases • Respiratory Syncytial Virus Infections • T Acute Lymphoblastic Leukemia • KMT2A

HOMOZYGOUS MALT1 DEFICIENCY PRESENTING IN INFANCY WITH PSEUDOMONAS AND ENTEROVIRAL INFECTIONS (ACAAI 2019) - "She completed a course of TMP/SMX, received intravenous immunoglobulin and was discharged on prophylactic TMP/SMX, acyclovir, fluconazole, palivizumab, and IVIG monthly. Discussion We report a pathogenic homozygous deficiency of MALT1 leading to severe susceptibility to bacterial, fungal, and viral infections. MALT1 promotes activation of NF-KB based transcription and eventual activation of lymphocytes."